|
|
Vaccine Detail
|
TriMixDC-MEL Vaccine |
| Vaccine Information |
- Vaccine Name: TriMixDC-MEL Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007114
- Type: Dendritic cell vaccine
- Status: Clinical trial
- Preparation: The vaccine consists of DCs pulsed with mRNA encoding full length tumor antigens (Benteyn et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is for Melanoma Cancer (Benteyn et al., 2013).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: TAA-specific CD8 T cells circulate in the blood stream. In total, 1/4 gp100-reponders (25%), 8/12 tyrosinase-responders (67%), 9/11 MAGE-C2-responders (82%), and 7/8 MAGE-A3 responders (88%) had CD8+ T cells that could be detected or found in both compartments (Benteyn et al., 2013).
|
| References |
Benteyn et al., 2013: Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). BioMed research international. 2013; 2013; 976383. [PubMed: 23509826].
|
|
